Human adenoviruses (HAdVs) are fatal to immuno-suppressed individuals, but no effective anti-HAdV therapy is available. Here, we present a novel image-based high-throughput screening (HTS) platform, which scores the full viral replication cycle from virus entry to dissemination of progeny and second-round infections. We analysed 1,280 small molecular weight compounds of the Prestwick Chemical Library (PCL) for interference with HAdV-C2 infection in a quadruplicate, blinded format, and performed robust image analyses and hit filtering. We present the entire set of the screening data including all images, image analyses and data processing pipelines. The data are made available at the Image Data Resource (IDR, idr0081). Our screen identified Nelfinavir mesylate as an inhibitor of HAdV-C2 multi-round plaque formation, but not single round infection. Nelfinavir has been FDA-approved for anti-retroviral therapy in humans. Our results underscore the power of image-based full cycle infection assays in identifying viral inhibitors with clinical potential.
Measurement(s)
nucleus • number of infected nuclei • infection index (number of infected nuclei/number of nuclei) • Plaque • fluorescent reporter intensity • percent cell viability
Technology Type(s)
epifluorescence microscopy • compound toxicity assay
Factor Type(s)
compound treatment
Sample Characteristic - Organism
Human mastadenovirus C
Machine-accessible metadata file describing the reported data:
https://doi.org/10.6084/m9.figshare.12594470...

A high-content image-based drug screen of clinical compounds against cell transmission of adenovirus

10.1038/s41597-020-00604-0